Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.
The pharmacokinetics of 20 mg torasemide i.v. has been studied in 7 healthy controls and 9 patients with varying degrees of renal impairment. Torasemide had a t1/2 of about 4h which was independent of kidney function, as the nonrenal clearance of torasemide was 3-times greater than its renal clearance. The active metabolite M 1 and the main metabolite M 5 were accumulated in chronic renal failure. In contrast to liver function, therefore, kidney failure does not have an important effect on the pharmacokinetics of torasemide.
Spahn
H
H
Pharmakologisches Institut für Naturwissenschaftler der Johann Wolfgang Goethe-Universität Frankfurt/Main, FRG.
Knauf
H
H
Mutschler
E
E
D004232:Diuretics / Q000737:chemistry / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D013449:Sulfonamides / Q000737:chemistry / Q000493:pharmacokinetics*; D000077786:Torsemide
D004232:Diuretics; D013449:Sulfonamides; D000077786:Torsemide